Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (5461)	1/31/1998 7:58:00 PM
From: Starlight	Respond to of 17367

George - No - he didn't refer to when there were only 52 patients. Also, he said that the trials were mainly going on in Texas and the U.K., as those were areas where there are more cases of meningo. He mentioned that it was "somewhat" seasonal, but I can't remember what time of the year more cases occured. I believe he said that right now there aren't many new cases. Sorry to be vague here. He feels that Neuprex will go to the FDA for approval by the end of this year. He also made the comment that the best time to buy biotechs was when they had drugs in Stage III trials just before they go to the FDA. Even if the stock has gone up somewhat by that time, he feels it's better to wait so that you don't have money tied up for so long before FDA approval. Betty

To: aknahow who wrote (5461)	2/1/1998 5:03:00 AM
From: Tharos	Respond to of 17367

George, Some interesting reading, thanks. Was interesting to find out the Glasco scale involves subjective criteria, although I'm confident a trained staff would score patients about the same.